生命科学资讯

Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters

Compass Pathways soars on second Phase 3 depression hit

Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink

Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

Gilead gets cancer drug from China-based Genhouse for $80M upfront

Pentagon adds, then withdraws, WuXi AppTec to Chinese military list

Lilly appeals retatrutide classification ruling in case that could impact compounders

Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity

Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class

Moderna's flu shot dilemma muddies 2028 break-even guidance

Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval

Immunic's private placement; Vertex's cystic fibrosis data in young kids

Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO

PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna

Ultragenyx to lay off about 130 employees after rough 2025

Icon's stock drops 40% after disclosing internal accounting probe

AbbVie sues over selection of Botox for IRA negotiations

Pharma pushes back on FDA plans to ease prescription-OTC drug switches

Novo Nordisk to expand Irish factory for Wegovy pill